🎗️Лента новостей
🎗️
Онкология
BioNTech stock falls after cancer trial misses key endpoint
BioNTech stock falls after cancer trial misses key endpoint Investing.com
Онкология
Отказ от курения при диагностированном раке почки связан со снижением риска летального исхода
Отказ от курения при диагностированном раке почки связан со снижением риска летального исхода Medvestnik
Онкология
Phase 1b/2 HERBOT Trial: First-Line HER2-Targeted Chemoimmunotherapy in Biliary Tract Cancer
Phase 1b/2 HERBOT Trial: First-Line HER2-Targeted Chemoimmunotherapy in Biliary Tract Cancer Oncodaily
Онкология
No approved treatment exists for colorectal cancer patients with cancer signals but clear scans. A trial will test one.
No approved treatment exists for colorectal cancer patients with cancer signals but clear scans. A trial will test one. Stock Titan
🎗️
Онкология
Онколог развеял миф о том, что использование смартфонов приводит к онкологии
Онколог развеял миф о том, что использование смартфонов приводит к онкологии https://saomos.news/
Онкология
Волгоградцам рассказали о факторах риска и важности ранней диагностики рака молочной железы
Волгоградцам рассказали о факторах риска и важности ранней диагностики рака молочной железы МТВ.онлайн
Онкология
От преддиабета до онкологии: почему казахстанцам не стоит пропускать скрининги
От преддиабета до онкологии: почему казахстанцам не стоит пропускать скрининги Almaty.tv
Онкология
BioNTech (BNTX) announced that the AHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy candidate BNT113 plus pembrolizumab compared with pembrolizumab al
BioNTech (BNTX) announced that the AHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy candidate BNT113 plus pembrolizumab compared with pembrolizumab al Newsquawk
Онкология
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer Yahoo Finance
Онкология
Lilly will supply two drugs for Prelude's planned breast cancer trial.
Lilly will supply two drugs for Prelude's planned breast cancer trial. Stock Titan
🎗️
Онкология
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer GlobeNewswire
Онкология
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer The Manila Times
🎗️
Онкология
DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division The Des Moines Register
🎗️
Онкология
Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026 Business Wire